Last reviewed · How we verify
Docetaxel, Oxaliplatin, S-1 and Durvalumab
Docetaxel, Oxaliplatin, S-1 and Durvalumab is a Small molecule drug developed by Asan Medical Center. It is currently in Phase 2 development.
At a glance
| Generic name | Docetaxel, Oxaliplatin, S-1 and Durvalumab |
|---|---|
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel, Oxaliplatin, S-1 and Durvalumab CI brief — competitive landscape report
- Docetaxel, Oxaliplatin, S-1 and Durvalumab updates RSS · CI watch RSS
- Asan Medical Center portfolio CI
Frequently asked questions about Docetaxel, Oxaliplatin, S-1 and Durvalumab
What is Docetaxel, Oxaliplatin, S-1 and Durvalumab?
Docetaxel, Oxaliplatin, S-1 and Durvalumab is a Small molecule drug developed by Asan Medical Center.
Who makes Docetaxel, Oxaliplatin, S-1 and Durvalumab?
Docetaxel, Oxaliplatin, S-1 and Durvalumab is developed by Asan Medical Center (see full Asan Medical Center pipeline at /company/asan-medical-center).
What development phase is Docetaxel, Oxaliplatin, S-1 and Durvalumab in?
Docetaxel, Oxaliplatin, S-1 and Durvalumab is in Phase 2.